Skip to content

Clinical Study on Grade 1 Essential Hypertension and Comparative Evaluation of Habbul Buzoor With Standard Control Drug Telmisartan in its Management.

A Clinical Study on Zightul Dam Qawi Ibtidai (Grade 1 Essential Hypertension)and Comparative Evaluation of Habbul Buzoor With Standard Control Drug Telmisartan in its Management

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037024
Enrollment
100
Registered
2021-10-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

Deptt of Moalejat Ajmal khan tibbiya college and hospital faculty of medicine AMU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed patients of Grade 1 (According to WHO/ISH,SBP-140-159 mm of Hg and DBP-90-99 mm of Hg)2 essential hypertension on three consecutive visits under optimal conditions. Patients of either gender. Patients in the age group of 18 to 60 years. No evidence of target organ damage should be present. Patients not taking any anti-hypertensive drugs prior to state of treatment. Clinically stable patients. Those who give written consent.

Exclusion criteria

Exclusion criteria: Patients of severe or malignant hypertension. Patients of Secondary hypertension. Patients below 18 years of age. Pregnant women and lactating mothers. Patients with unstable systemic disorders like liver,kidney or heart diseases etc. Patients with Clinical or laboratory evidence of target organ damage. Terminally ill patients like infectious diseases ,AIDS,Tuberculosis etc. Smokers and alcoholics.Patients who do not sign informed consent form.

Design outcomes

Primary

MeasureTime frame
Efficacy will be assessed clinically by recording reading of systolic and diastolic blood pressure and relief in symptoms(if present) Timepoint: 2 months with every 2 week followup

Secondary

MeasureTime frame
relief in symptoms(if present) Timepoint: 2 months with every 2 week followup

Countries

India

Contacts

Public ContactProfessor Tabassum Latafat

Department of Moalejat AKTCH AMU Aligarh

sadaf68.sk@gmail.com7417211521

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026